Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Nov 24, 2024 3:41pm
233 Views
Post# 36328169

Silence Continues ………

Silence Continues ………

 

 

But so does the nefarious shorting algorithms! 

 

In my humble opinion the lack of communication and updates, just plays into the hands of those shorting.

 

I find it mind boggling that we have been dosing at 5 sites in Turkey for approximately 10 months and not a word, not a peep from management!

 

This stock will never move up with new buyers, bug buyers, institutional buyers stepping in. We cannot rely on retail, which quite frankly is exhausted after 2 years of aggressive shorting by CIBC, Scotia & National banks.

 

The TSXV is the wild wild west, no rules, no enforcement, just look at the junior mining sector who have complained for years about nefarious shorting, naked shorting with TSXV just taking the see no evil, hear no evil stance.

 

Now back to communication, it is mind boggling that after 10 months of dosing at 5 sites in Turkey that we hear nothing from management.

 

They attend two conferences, one in California and one in Stockholm yet nothing positive report.

 

Check out the level 2 each day, anemic volume, same buyers on the bid side, generally the two market makers only, the sell side is CIBC, Scotia and National Bank.

 

Management needs to promote and tell the story but a big part of the story is we are 10 months into a level 2 AKI trial at 5 sites in Turkey, plus additional 1 in Calgary. Zero adverse reactions but nothing material to update markets.

 

What was the purpose of the two conferences? What was the goal to attend and present? Were those goals attained? What was achieved?

 

The AKI trial investors would like to know:

 

How many patients dosed to-date?

 

Has there been any adverse reactions?

 

Why was trial extended from Feb 2025 completion to August 2025?

 

Why did management wait nearly 5 months to start the AKI approval process at Canadian sites, why did they not start the process at the same time as starting Turkey, knowing Canada takes a very long time?

 

Why is there no new buyers stepping in?

 

Why does Arch have zero (0%) institutional investor ownership and what is management’s plan for this?

 

Why does management feel Arch is so undervalued compared to similar staged peers and what are they planning to do to resolve this.

 

Nothing updated on Pontiac trial. I realize it is not our trial but I am sure they must have something to update us on?

 

Have they identified all the sites?

 

Do they have ethics approval yet?

 

Anticipated Start date?

<< Previous
Bullboard Posts